TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties (Q39486061)

12 September 2017

title

TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties (English)

1 reference

12 September 2017

1 reference

12

B. W. Dymock

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

author name string

K. C. Goh

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

V. Novotny-Diermayr

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

S. Hart

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

L. C. Ong

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

Y. K. Loh

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

A. Cheong

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

Y. C. Tan

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

C. Hu

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

R. Jayaraman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

A. D. William

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

E. T. Sun

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

K. H. Ong

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

K. Ethirajulu

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

F. Burrows

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

J. M. Wood

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21860433

10 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21860433

10 December 2024

publication date

23 August 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

26

1 reference

12 September 2017

issue

2

1 reference

12 September 2017

page(s)

236-243

1 reference

Targeted Inhibition of Kinases in Cancer Therapy

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Novel inhibitors in development for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Pharmacological inhibitors of cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

The JAK/STAT signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Recent advances in the bcr-abl negative chronic myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Emerging Flt3 kinase inhibitors in the treatment of leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

The exploration of macrocycles for drug discovery--an underexploited structural class

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Cell cycle kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Activation mechanisms of STAT5 by oncogenic Flt3-ITD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Kinases as drug discovery targets in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34 /CD38− cells and sensitizes them to antileukemia agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

inferred from DOI database lookup

7 January 2021

based on heuristic

Expression of p‐JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038/LEU.2011.218

inferred from DOI database lookup

7 January 2021

based on heuristic

Antiangiogenic treatments and mechanisms of action in renal cell carcinoma

https://api.crossref.org/works/10.1038/LEU.2011.218

2

1 reference

Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis

10 December 2024

https://api.crossref.org/works/10.1038/LEU.2011.218

27

1 reference

10 December 2024

Identifiers

DOI

10.1038/LEU.2011.218

1 reference

12 September 2017

1 reference